Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
R Barroso-Sousa, WT Barry, AC Garrido-Castro… - JAMA …, 2018 - jamanetwork.com
Importance If not promptly recognized, endocrine dysfunction can be life threatening. The
incidence and risk of developing such adverse events (AEs) following the use of immune
checkpoint inhibitor (ICI) regimens are unknown. Objective To compare the incidence and
risk of endocrine AEs following treatment with US Food and Drug Administration–approved
ICI regimens. Data Sources A PubMed search through July 18, 2016, using the following
keywords was performed:“ipilimumab,”“MDX-010,”“nivolumab,”“BMS-963558,”“ …
incidence and risk of developing such adverse events (AEs) following the use of immune
checkpoint inhibitor (ICI) regimens are unknown. Objective To compare the incidence and
risk of endocrine AEs following treatment with US Food and Drug Administration–approved
ICI regimens. Data Sources A PubMed search through July 18, 2016, using the following
keywords was performed:“ipilimumab,”“MDX-010,”“nivolumab,”“BMS-963558,”“ …